Bay­er bails on chron­ic cough drug from Evotec, putting the ki­bosh on lead med in mul­ti-tar­get col­lab­o­ra­tion

Bay­er and dis­cov­ery out­fit Evotec have long been bo­som bud­dies, cy­cling through part­ner­ships for the bet­ter part of a decade. But now, Bay­er is dump­ing rights to a cough drug out of that col­lab­o­ra­tion, cit­ing dwin­dling re­turns on a com­pet­i­tive mar­ket.

Bay­er has dis­con­tin­ued de­vel­op­ment of eli­apix­ant and will hand back full rights to the drug to Evotec af­ter the Ger­man drug gi­ant “con­clud­ed that the over­all ben­e­fit no longer out­weighs the risk in the ac­tive­ly pur­sued in­di­ca­tions,” ac­cord­ing to a re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER